Inventiva S.A. (IVA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 6-K for Q2 FY2025, filed Sep 29, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IVA SEC filings page.
Inventiva S.A. (IVA) reported $9.5M in revenue for fiscal year 2024, down 50.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Inventiva S.A.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Inventiva S.A., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Inventiva S.A. had 96M shares outstanding at the end of fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Inventiva S.A. scores 20/100 among other emerging companies.
Inventiva S.A. spent $94.1M on research and development in fiscal year 2024, which was 85.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Inventiva S.A. scores 99/100 among other emerging companies.
Inventiva S.A. reported revenue of $9.5M in fiscal year 2024, against $19.3M in fiscal year 2023. Revenue Progress ranks emerging companies on the three-year path of that line, and Inventiva S.A. scores 25/100 among other emerging companies.
Inventiva S.A.'s operations used $88.9M of cash in fiscal year 2024, against $90.3M used in fiscal year 2023. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Inventiva S.A. scores 22/100 among other emerging companies.
Not available for Inventiva S.A., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Inventiva S.A. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Inventiva S.A. reported a net loss of $190.7M while operations used $88.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Inventiva S.A. reported an operating loss of $101.0M against $12.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2025.
Cash & Balance Sheet
Inventiva S.A. held $143.7M in cash as of Q2 2025; no long-term debt figure is on record for that period.
Not reported for Q2 2025.
Not reported for Q2 2025.
Margins & Returns
None of these metrics is reported for Q2 2025.
Capital Allocation
None of these metrics is reported for Q2 2025.
IVA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
IVA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'256-K | Q4'246-K | Q2'246-K | Q4'2320-F | Q2'236-K | Q4'2220-F | Q4'2120-F | Q4'2020-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $210.6M+398.8% | $123.1M+60.0% | $42.2M-45.4% | $76.9M-38.0% | $77.3M | $124.1M-10.1% | $138.1M-18.7% | $169.9M+165.7% |
| Current Assets | $203.4M+563.8% | $115.4M+116.5% | $30.6M-46.4% | $53.3M-53.2% | $57.2M | $113.8M-13.0% | $130.8M-19.6% | $162.7M+196.4% |
| Cash & Equivalents | $143.7M+1222.0% | $100.0M+235.7% | $10.9M-68.1% | $29.8M-67.9% | $34.1M | $92.8M-5.3% | $98.0M-24.2% | $129.3M+221.2% |
| Inventory | N/A | $0-100.0% | $421K-3.9% | $461K+15.6% | $438K | $399K-10.1% | $444K+13.4% | $391K-9.9% |
| Accounts Receivable | $12.7M+1362.1% | $550K-86.9% | $867K | $4.2Mn/m | N/A | $0-100.0% | $4.5M | N/A |
| Total Liabilities | $221.1M+74.2% | $233.5M+107.8% | $126.9M+48.1% | $112.4M+48.9% | $85.7M | $75.5M+101.3% | $37.5M+10.6% | $33.9M+93.9% |
| Current Liabilities | $68.8M+33.4% | $125.0M+125.2% | $51.6M+24.9% | $55.5M+68.9% | $41.3M | $32.8M+27.0% | $25.9M+52.1% | $17.0M+9.3% |
| Non-Current Liabilities | $152.3M+102.2% | $108.6M+90.8% | $75.3M+69.6% | $56.9M+33.5% | $44.4M | $42.6M+266.7% | $11.6M-31.2% | $16.9M+782.7% |
| Long-Term Debt | N/A | N/A | $78.6M+83.4% | $59.8M+45.1% | $42.9M | $41.2M+312.2% | $10.0M-18.5% | $12.3M+1093268.8% |
| Total Equity | -$10.5Mn/m | -$110.4Mn/m | -$84.7Mn/m | -$35.4M-172.8% | -$8.4M | $48.7M-51.6% | $100.6M-26.1% | $136.0M+192.7% |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$41.1Mn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.
IVA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
IVA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$110.4M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.92), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Inventiva S.A. IVA | FY2024 | $9.5M | -$190.7M | N/A | $870.5M | 42/100 |
| Immunome, Inc. IMNM | FY2025 | $6.9M | -$212.4M | N/A | $2.2B | 50/100 |
| Geron Corp GERN | FY2025 | N/A | -$83.5M | N/A | $738.8M | — |
| Praxis Precision Medicines, Inc. PRAX | FY2025 | $0 | -$303.3M | N/A | $7.5B | — |
| Anavex Life Sciences AVXL | FY2025 | N/A | -$46.4M | N/A | $121.4M | — |
| BridgeBio Oncology Therapeutics, Inc. BBOT | FY2025 | N/A | -$134.0M | N/A | $215.7M | — |
Where Inventiva S.A. Ranks
Frequently Asked Questions
What is Inventiva S.A.'s annual revenue?
Inventiva S.A. (IVA) reported $9.5M in total revenue for fiscal year 2024. This represents a -50.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Inventiva S.A.'s revenue growing?
Inventiva S.A. (IVA) revenue declined by 50.8% year-over-year, from $19.3M to $9.5M in fiscal year 2024.
Is Inventiva S.A. profitable?
No, Inventiva S.A. (IVA) reported a net loss of $190.7M in fiscal year 2024.
What is Inventiva S.A.'s operating cash flow?
Inventiva S.A. (IVA) recorded an outflow of $88.9M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Inventiva S.A.'s total assets?
Inventiva S.A. (IVA) had $123.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Inventiva S.A. spend on research and development?
Inventiva S.A. (IVA) invested $94.1M in research and development during fiscal year 2024.
What is Inventiva S.A.'s current ratio?
Inventiva S.A. (IVA) had a current ratio of 0.92 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Inventiva S.A.'s return on assets (ROA)?
Inventiva S.A. (IVA) had a return on assets of -154.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Inventiva S.A.'s P/E ratio?
Inventiva S.A. (IVA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $870.5M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Inventiva S.A.'s price-to-sales ratio?
Inventiva S.A. (IVA) trades at 91.4x sales, its market capitalization divided by $9.5M revenue, FY2024. The market capitalization is $870.5M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Inventiva S.A.'s debt-to-equity ratio negative or not reported?
Inventiva S.A. (IVA) has negative shareholder equity of -$110.4M as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Inventiva S.A.'s Piotroski F-Score?
Inventiva S.A. (IVA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inventiva S.A.'s earnings high quality?
Inventiva S.A. (IVA) reported a net loss of $190.7M while operations used $88.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Inventiva S.A. cover its interest payments?
Inventiva S.A. (IVA) reported an operating loss of $101.0M against $12.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Inventiva S.A.?
Inventiva S.A. (IVA) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Inventiva S.A. it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.